Description
Evrenzo (Roxadustat) is an oral prescription medication used to treat anemia caused by chronic kidney disease (CKD) in adult patients. The medication stimulates the production of red blood cells in the body by mimicking the effect of hypoxia (low oxygen levels). Evrenzo comes in tablet form for oral administration.
Uses:
Evrenzo is used to treat anemia in adult patients with chronic kidney disease who are not on dialysis or patients who are on dialysis. The medication helps to increase the production of red blood cells and improve hemoglobin levels in patients with anemia.
Storage Conditions:
Evrenzo tablets should be stored at room temperature, between 15°C to 30°C (59°F to 86°F). The tablets should be kept in the original packaging to protect them from light and moisture.
Mechanism of Action:
Evrenzo works by activating the hypoxia-inducible factors (HIFs), which stimulate the production of erythropoietin (EPO) and other factors necessary for the production of red blood cells. Evrenzo replicates the effect of hypoxia, which leads to increased levels of EPO and an increased production of red blood cells, improving the anemia in CKD patients.
HOW TO USE:
Evrenzo is taken orally once daily, with or without food. The dose of Evrenzo should be adjusted by the healthcare provider based on the patient’s hemoglobin levels. The starting dose for patients not on dialysis is 1mg per kg body weight, while for patients on dialysis, it is 0.5mg per kg body weight. The medication should be swallowed whole and not broken, crushed or chewed. Patients should never exceed the prescribed dose of Evrenzo.
Precautions:
• Patients with uncontrolled hypertension should not use Evrenzo.
• Patients with a history of blood clots may be at risk for thrombotic events while using Evrenzo, and caution should be exercised.
• The risk of cardiovascular and cerebrovascular events may increase in patients taking Evrenzo, especially those with underlying cardiovascular disease.
Drug Interactions:
Evrenzo may interact with other drugs such as warfarin, which may increase the risk of bleeding. Patients should inform their healthcare provider of all medications, supplements, or herbal products they are taking before starting treatment with Evrenzo.
Contraindications:
• Evrenzo should not be used in patients with a history of hypersensitivity to roxadustat or any of its components.
• Evrenzo is contraindicated in patients on dialysis who have not completed the dialysis session.
• The safety and effectiveness of Evrenzo in pediatric patients have not been established.
Overdose:
In case of an overdose, the patient should contact a healthcare provider immediately. Symptoms of overdose include nausea, vomiting, dizziness, and headache.
Adverse Reactions:
Common adverse reactions associated with the use of Evrenzo include hypertension, diarrhea, nausea, vomiting, headache, and peripheral edema. Patients should contact their healthcare provider if they experience any unusual reactions while using Evrenzo.
In conclusion, Evrenzo (Roxadustat) is an oral medication used to treat anemia in adults with chronic kidney disease. The medication stimulates the production of red blood cells by imitating the effect of hypoxia. It comes in tablet form to be taken orally once daily, with or without food, in the prescribed dosage. Evrenzo should be stored at room temperature, between 15°C to 30°C, in its original packaging. The medication has several contraindications, drug interactions and precautions that should be taken into consideration before use. Adverse reactions associated with Evrenzo include hypertension, nausea, vomiting, headache, and diarrhea. Patients should always seek medical attention if they experience any unusual reactions while on medication.
Reviews
There are no reviews yet.